Remus Pharmaceuticals Limited (NSE:REMUS)
India
· Delayed Price · Currency is INR 878.55
-11.25 (-1.26%)
At close: Jul 10, 2025
Remus Pharmaceuticals Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 |
Cash & Equivalents | 81.4 | 268.68 | 30.38 | 11.49 | 8.31 | Upgrade
|
Short-Term Investments | - | 24.77 | - | - | - | Upgrade
|
Cash & Short-Term Investments | 81.4 | 293.45 | 30.38 | 11.49 | 8.31 | Upgrade
|
Cash Growth | -72.26% | 865.87% | 164.51% | 38.30% | -30.68% | Upgrade
|
Accounts Receivable | 1,080 | 1,145 | 48.48 | 29.15 | 36.04 | Upgrade
|
Receivables | 1,290 | 1,145 | 48.48 | 29.15 | 36.04 | Upgrade
|
Inventory | 515.6 | 428.81 | 2.87 | 15.89 | 11.51 | Upgrade
|
Prepaid Expenses | - | 0.4 | 0.49 | 0.07 | - | Upgrade
|
Other Current Assets | 327.1 | 229.96 | 31.22 | 20.34 | 19.15 | Upgrade
|
Total Current Assets | 2,214 | 2,097 | 113.44 | 76.94 | 75 | Upgrade
|
Property, Plant & Equipment | 68.3 | 22.75 | 25.13 | 3.09 | 3.92 | Upgrade
|
Long-Term Investments | 1,861 | 205.49 | 206.16 | 30.68 | 0.67 | Upgrade
|
Goodwill | 87.3 | 93.37 | - | - | - | Upgrade
|
Other Intangible Assets | 2.6 | 0.28 | 0.5 | - | - | Upgrade
|
Long-Term Deferred Tax Assets | - | 8.41 | 1.27 | 0.41 | 0.6 | Upgrade
|
Other Long-Term Assets | 93.3 | 145.04 | 0.12 | 47.49 | 30.31 | Upgrade
|
Total Assets | 4,326 | 2,573 | 346.61 | 158.6 | 110.5 | Upgrade
|
Accounts Payable | 712.9 | 937.03 | 35.31 | 46.73 | 51.59 | Upgrade
|
Accrued Expenses | - | 9.31 | 8.61 | 2.75 | 9.63 | Upgrade
|
Short-Term Debt | - | 83.38 | 6.38 | - | - | Upgrade
|
Current Portion of Long-Term Debt | 174.8 | 2.14 | 2.16 | 0.93 | 0.87 | Upgrade
|
Current Portion of Leases | 5.1 | - | - | - | - | Upgrade
|
Current Income Taxes Payable | 28.1 | 14.32 | 6.75 | 4.71 | 3.58 | Upgrade
|
Other Current Liabilities | 294.4 | 448.64 | 22.41 | 36.71 | 11.24 | Upgrade
|
Total Current Liabilities | 1,215 | 1,495 | 81.62 | 91.84 | 76.92 | Upgrade
|
Long-Term Debt | 33.3 | 29.95 | 70.89 | 0.99 | 1.92 | Upgrade
|
Long-Term Leases | 16.6 | - | - | - | - | Upgrade
|
Long-Term Deferred Tax Liabilities | 229 | - | - | - | - | Upgrade
|
Other Long-Term Liabilities | 6.7 | 0.4 | - | - | - | Upgrade
|
Total Liabilities | 1,501 | 1,529 | 155.26 | 92.82 | 80.04 | Upgrade
|
Common Stock | 58.9 | 14.73 | 10.85 | 10 | 0.1 | Upgrade
|
Additional Paid-In Capital | - | 504.74 | 41.65 | - | - | Upgrade
|
Retained Earnings | - | 348.33 | 138.86 | 55.78 | 30.36 | Upgrade
|
Comprehensive Income & Other | 2,500 | 0.77 | - | - | - | Upgrade
|
Total Common Equity | 2,559 | 868.57 | 191.36 | 65.78 | 30.46 | Upgrade
|
Minority Interest | 266.9 | 174.77 | - | - | - | Upgrade
|
Shareholders' Equity | 2,826 | 1,043 | 191.36 | 65.78 | 30.46 | Upgrade
|
Total Liabilities & Equity | 4,326 | 2,573 | 346.61 | 158.6 | 110.5 | Upgrade
|
Total Debt | 229.8 | 115.47 | 79.43 | 1.92 | 2.79 | Upgrade
|
Net Cash (Debt) | -148.4 | 177.98 | -49.05 | 9.57 | 5.52 | Upgrade
|
Net Cash Growth | - | - | - | 73.48% | -34.24% | Upgrade
|
Net Cash Per Share | -16.64 | 15.70 | -6.00 | 1.20 | 0.69 | Upgrade
|
Filing Date Shares Outstanding | 6.05 | 11.78 | 8.68 | 8.68 | 8 | Upgrade
|
Total Common Shares Outstanding | 6.05 | 11.78 | 8.68 | 8.68 | 8 | Upgrade
|
Working Capital | 998.4 | 602.58 | 31.82 | -14.9 | -1.91 | Upgrade
|
Book Value Per Share | 423.08 | 73.71 | 22.05 | 7.58 | 3.81 | Upgrade
|
Tangible Book Value | 2,469 | 774.93 | 190.85 | 65.78 | 30.46 | Upgrade
|
Tangible Book Value Per Share | 408.21 | 65.76 | 21.99 | 7.58 | 3.81 | Upgrade
|
Buildings | - | 3.28 | 3.28 | - | - | Upgrade
|
Machinery | - | 37.56 | 31.07 | 7.89 | 7.18 | Upgrade
|
Construction In Progress | - | 0.09 | 0.22 | - | - | Upgrade
|
Updated Nov 9, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.